These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. Zimmermann TS; Karsten V; Chan A; Chiesa J; Boyce M; Bettencourt BR; Hutabarat R; Nochur S; Vaishnaw A; Gollob J Mol Ther; 2017 Jan; 25(1):71-78. PubMed ID: 28129130 [TBL] [Abstract][Full Text] [Related]
8. Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases. Li Q; Yin K; Ma HP; Liu HH; Li S; Luo X; Hu R; Zhang WW; Lv ZS; Niu XL; Gu MH; Li CL; Liu YS; Liu YJ; Li HB; Li N; Li C; Gu WW; Li JJ Mol Ther; 2024 Mar; 32(3):637-645. PubMed ID: 38204163 [TBL] [Abstract][Full Text] [Related]
9. Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates. Brown CR; Gupta S; Qin J; Racie T; He G; Lentini S; Malone R; Yu M; Matsuda S; Shulga-Morskaya S; Nair AV; Theile CS; Schmidt K; Shahraz A; Goel V; Parmar RG; Zlatev I; Schlegel MK; Nair JK; Jayaraman M; Manoharan M; Brown D; Maier MA; Jadhav V Nucleic Acids Res; 2020 Dec; 48(21):11827-11844. PubMed ID: 32808038 [TBL] [Abstract][Full Text] [Related]
11. Metabolically Stable Anomeric Linkages Containing GalNAc-siRNA Conjugates: An Interplay among ASGPR, Glycosidase, and RISC Pathways. Kandasamy P; Mori S; Matsuda S; Erande N; Datta D; Willoughby JLS; Taneja N; O'Shea J; Bisbe A; Manoharan RM; Yucius K; Nguyen T; Indrakanti R; Gupta S; Gilbert JA; Racie T; Chan A; Liu J; Hutabarat R; Nair JK; Charisse K; Maier MA; Rajeev KG; Egli M; Manoharan M J Med Chem; 2023 Feb; 66(4):2506-2523. PubMed ID: 36757090 [TBL] [Abstract][Full Text] [Related]
12. Novel Cluster and Monomer-Based GalNAc Structures Induce Effective Uptake of siRNAs in Vitro and in Vivo. Sharma VK; Osborn MF; Hassler MR; Echeverria D; Ly S; Ulashchik EA; Martynenko-Makaev YV; Shmanai VV; Zatsepin TS; Khvorova A; Watts JK Bioconjug Chem; 2018 Jul; 29(7):2478-2488. PubMed ID: 29898368 [TBL] [Abstract][Full Text] [Related]
13. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307 [TBL] [Abstract][Full Text] [Related]
14. GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics. Springer AD; Dowdy SF Nucleic Acid Ther; 2018 Jun; 28(3):109-118. PubMed ID: 29792572 [TBL] [Abstract][Full Text] [Related]
15. The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of McDougall R; Ramsden D; Agarwal S; Agarwal S; Aluri K; Arciprete M; Brown C; Castellanos-Rizaldos E; Charisse K; Chong S; Cichocki J; Fitzgerald K; Goel V; Gu Y; Guenther D; Habtemariam B; Jadhav V; Janas M; Jayaraman M; Kurz J; Li J; Liu J; Liu X; Liou S; Maclauchlin C; Maier M; Manoharan M; Nair JK; Robbie G; Schmidt K; Smith P; Theile C; Vaishnaw A; Waldron S; Xu Y; Zhang X; Zlatev I; Wu JT Drug Metab Dispos; 2022 Jun; 50(6):781-797. PubMed ID: 34154993 [TBL] [Abstract][Full Text] [Related]